{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:39:20Z","timestamp":1784259560235,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-024-04798-2","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:49:29Z","timestamp":1736729369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic impact and risk factors of severe neutropenia in the early phase of treatment with trifluridine-tipiracil for metastatic colorectal cancer patients: a single-center retrospective study"],"prefix":"10.1007","volume":"40","author":[{"given":"Yoshiro","family":"Omori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-0222","authenticated-orcid":false,"given":"Satoshi","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Kawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ishimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Tokuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"20","key":"4798_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919. https:\/\/doi.org\/10.1056\/NEJMoa1414325","journal-title":"N Engl J Med"},{"issue":"9863","key":"4798_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"issue":"18","key":"4798_CR3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388(18):1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963","journal-title":"N Engl J Med"},{"issue":"1","key":"4798_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clcc.2016.07.005","volume":"16","author":"S Hamauchi","year":"2017","unstructured":"Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T et al (2017) Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer 16(1):51\u201357. https:\/\/doi.org\/10.1016\/j.clcc.2016.07.005","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"4798_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/ol.2021.13044","volume":"22","author":"D Kamiimabeppu","year":"2021","unstructured":"Kamiimabeppu D, Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Yoshino K et al (2021) Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine\/tipiracil plus bevacizumab. Oncol Lett 22(5):783. https:\/\/doi.org\/10.3892\/ol.2021.13044","journal-title":"Oncol Lett"},{"key":"4798_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12885-016-2491-y(Electronic)):467","volume":"16","author":"PM Kasi","year":"2016","unstructured":"Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK et al (2016) Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 16:467. https:\/\/doi.org\/10.1186\/s12885-016-2491-y(Electronic)):467","journal-title":"BMC Cancer"},{"issue":"3","key":"4798_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-020-04129-6","volume":"86","author":"Y Nose","year":"2020","unstructured":"Nose Y, Kagawa YA-O, Hata T, Mori R, Kawai K, Naito A et al (2020) Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study. Cancer Chemother Pharmacol 86(3):427\u2013433. https:\/\/doi.org\/10.1007\/s00280-020-04129-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4798_CR8","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12885-023-11618-3","volume":"23","author":"D Watanabe","year":"2023","unstructured":"Watanabe D, Fujii H, Ohata K, Iihara H, Makiyama A, Kobayashi R et al (2023) Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. BMC Cancer 23(1):1078. https:\/\/doi.org\/10.1186\/s12885-023-11618-3","journal-title":"BMC Cancer"},{"issue":"1","key":"4798_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E et al (2020) Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann Oncol 31(1):88\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.005","journal-title":"Ann Oncol"},{"issue":"8","key":"4798_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147(8):573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010","journal-title":"Ann Intern Med"},{"key":"4798_CR11","unstructured":"National Cancer (2017) Institute Common terminology criteria for adverse events (CTCAE), v.5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 7 Jun 2023"},{"issue":"1","key":"4798_CR12","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/s41598-021-93732-5","volume":"11","author":"A Fern\u00e1ndez Montes","year":"2021","unstructured":"Fern\u00e1ndez Montes A, Carmona-Bayonas A, Jimenez-Fonseca P, V\u00e1zquez Rivera F, Martinez Lago N, Covela R\u00faa M et al (2021) Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine\/tipiracil: real-world vs clinical trial data. Sci Rep 11(1):14321. https:\/\/doi.org\/10.1038\/s41598-021-93732-5","journal-title":"Sci Rep"},{"key":"4798_CR13","doi-asserted-by":"publisher","unstructured":"Tabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, et al (2020) Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. LID \u2013 https:\/\/doi.org\/10.1136\/esmoopen-2020-000752. ESMO Open 4(2059\u20137029 (Electronic)):e000752. LID - e000752","DOI":"10.1136\/esmoopen-2020-000752"},{"issue":"1","key":"4798_CR14","doi-asserted-by":"publisher","first-page":"17931","DOI":"10.1038\/s41598-023-45244-7","volume":"13","author":"M Shiroyama","year":"2023","unstructured":"Shiroyama M, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T et al (2023) Renal impairment as a risk factor for trifluridine\/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study. Sci Rep 13(1):17931. https:\/\/doi.org\/10.1038\/s41598-023-45244-7","journal-title":"Sci Rep"},{"issue":"3","key":"4798_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","volume":"88","author":"MW Saif","year":"2021","unstructured":"Saif MW, Becerra CR, Fakih MG, Sun W, Popovic L, Krishnamurthi S et al (2021) A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother Pharmacol 88(3):485\u2013497. https:\/\/doi.org\/10.1007\/s00280-021-04308-z","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04798-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:49:31Z","timestamp":1736729371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04798-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4798"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04798-2","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"26 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11"}}